Amit Sachdev - May 17, 2021 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role: EVP, Chief Patient Officer
Signature: /s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol: VRTX
Transactions as of: May 17, 2021
Transactions value $: -$9,736
Form type: 4
Date filed: 5/19/2021, 04:08 PM
Next filing: Nov 16, 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRTX	Common Stock	Sale	-$1.72K	-8	-0.02%	$215.59	40.2K	May 17, 2021	Direct	F1, F2, F3
transaction	VRTX	Common Stock	Sale	-$6.92K	-32	-0.08%	$216.40	40.1K	May 17, 2021	Direct	F1, F3, F4
transaction	VRTX	Common Stock	Sale	-$1.09K	-5	-0.01%	$217.27	40.1K	May 17, 2021	Direct	F1, F3, F5
holding	VRTX	Common Stock						882	May 17, 2021	401(k)
holding	VRTX	Common Stock						7.37K	May 17, 2021	Held in Trust

Showing 1 to 5 of 5 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1.
F2	Open market sales reported on this line occurred at a weighted average price of $215.59 (range $214.94 to $215.93).
F3	Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4	Open market sales reported on this line occurred at a weighted average price of $216.40 (range $215.95 to $216.91).
F5	Open market sales reported on this line occurred at a weighted average price of $217.27 (range $217.05 to $217.46).